newsfilter
← Latest News
Business Wire·

Furiex Confirms Takeda’s Announcement on the Acceptance of the European Medicines Agency Submission of Alogliptin for the Treatment of Type 2 Diabetes

MORRISVILLE, N.C.--(BUSINESS WIRE)--Furiex Pharmaceuticals, Inc. (NASDAQ: FURX) today confirmed that Takeda Global Research & Development Centre (Europe) Ltd. received confirmation on the acceptance of the submission of a Marketing Authorization Application, or MAA, from the European Medicines Agency for alogliptin, a selective dipeptidyl peptidase IV, or DPP-4, inhibitor for the treatment of type 2 diabetes.